Aficamten, Aficamten, Aficamten, Aficamten
CY 6022
Phase 2 small_molecule active
Quick answer
Aficamten, Aficamten, Aficamten, Aficamten for Symptomatic hypertrophic cardiomyopathy (HCM) is a Phase 2 program (small_molecule) at Cytokinetics (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cytokinetics (Ireland) Limited
- Indication
- Symptomatic hypertrophic cardiomyopathy (HCM)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active